title: Recent FDA approvals and changes.
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D002648:Child; D018849:Controlled Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000008:administration & dosage*; D017277:Drug Approval; D004348:Drug Labeling; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage*; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D013007:Growth Hormone-Releasing Hormone; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000099227:Abacavir; C451734:etravirine; C479538:tesamorelin